Loading…
Simultaneous very low dose mifepristone and vaginal misoprostol for medical abortion
This pilot study was designed to evaluate the outcome of medical abortion following simultaneous mifepristone (100 mg) and misoprostol (800 μg). Enrollees had gestational ages up to 56 days and desired a medical abortion. They received 100 mg of mifepristone orally and 800 μg of misoprostol vaginall...
Saved in:
| Published in: | Contraception (Stoneham) 2006-05, Vol.73 (5), p.525-527 |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c411t-6e2cba4d3055fd3f37a14e750f8ed9d0aa54343e27f746cfe28a9cf1519c01633 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c411t-6e2cba4d3055fd3f37a14e750f8ed9d0aa54343e27f746cfe28a9cf1519c01633 |
| container_end_page | 527 |
| container_issue | 5 |
| container_start_page | 525 |
| container_title | Contraception (Stoneham) |
| container_volume | 73 |
| creator | Kapp, Nathalie Borgatta, Lynn Ellis, Sacheen Carr Stubblefield, Phillip |
| description | This pilot study was designed to evaluate the outcome of medical abortion following simultaneous mifepristone (100 mg) and misoprostol (800 μg).
Enrollees had gestational ages up to 56 days and desired a medical abortion. They received 100 mg of mifepristone orally and 800 μg of misoprostol vaginally. Follow-up examination occurred in 2–7 days. A phone call 3 weeks later assessed symptoms and acceptability. A 95% success rate, as seen in higher dose studies, gives a 95% confidence interval of 88–100% for 40 subjects.
Forty women were enrolled; 39 women had follow-up visits. Completed medical abortion was confirmed for 35 (90%) of 39 women. Four women had uterine aspiration. Two patients required repeat misoprostol. Median time from medication to abortion was 7 h. Most women (92%) strongly preferred taking all medications in the clinic.
The simultaneous administration of vaginal misoprostol with 100 mg of oral mifepristone had the outcome of completed abortion within the predicted confidence interval. In addition, simultaneous dosing was highly acceptable. |
| doi_str_mv | 10.1016/j.contraception.2005.12.011 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67879422</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0010782406000060</els_id><sourcerecordid>67879422</sourcerecordid><originalsourceid>FETCH-LOGICAL-c411t-6e2cba4d3055fd3f37a14e750f8ed9d0aa54343e27f746cfe28a9cf1519c01633</originalsourceid><addsrcrecordid>eNqNkE1LJDEQhoMoOqv-BWkQvXVblf5IN3taxN0VBA_qOWTSFcnQ0xmTnhH_vTXMgHjzFEg9lbzvI8QlQoGAzc2isGGcorG0mnwYCwlQFygLQDwQM2xVl0ON7aGYASDkqpXVifiV0gIAVFerY3GCTSMVlN1MPD_55XqYzEhhnbINxY9sCO9ZHxJlS-9oFX2awkiZGftsY179aAYepLCKgQdD5kLMltR7y_dmHuI20pk4cmZIdL4_T8XL37vn2__5w-O_-9s_D7mtEKe8IWnnpupLqGvXl65UBitSNbiW-q4HY-qqrEqSyqmqsY5kazrrsMbOsoiyPBXXu3c5zNua0qQ5maVh2NXRjWIZlZQM_t6BllOnSE5zr6WJHxpBb6Xqhf4mVW-lapSapfL2xf6b9Zyrfu3uLTJwtQdMYg8umtH69MUppdpWtczd7ThiKRtPUSfrabSsL5KddB_8jwJ9Aru9nzg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67879422</pqid></control><display><type>article</type><title>Simultaneous very low dose mifepristone and vaginal misoprostol for medical abortion</title><source>Elsevier</source><creator>Kapp, Nathalie ; Borgatta, Lynn ; Ellis, Sacheen Carr ; Stubblefield, Phillip</creator><creatorcontrib>Kapp, Nathalie ; Borgatta, Lynn ; Ellis, Sacheen Carr ; Stubblefield, Phillip</creatorcontrib><description>This pilot study was designed to evaluate the outcome of medical abortion following simultaneous mifepristone (100 mg) and misoprostol (800 μg).
Enrollees had gestational ages up to 56 days and desired a medical abortion. They received 100 mg of mifepristone orally and 800 μg of misoprostol vaginally. Follow-up examination occurred in 2–7 days. A phone call 3 weeks later assessed symptoms and acceptability. A 95% success rate, as seen in higher dose studies, gives a 95% confidence interval of 88–100% for 40 subjects.
Forty women were enrolled; 39 women had follow-up visits. Completed medical abortion was confirmed for 35 (90%) of 39 women. Four women had uterine aspiration. Two patients required repeat misoprostol. Median time from medication to abortion was 7 h. Most women (92%) strongly preferred taking all medications in the clinic.
The simultaneous administration of vaginal misoprostol with 100 mg of oral mifepristone had the outcome of completed abortion within the predicted confidence interval. In addition, simultaneous dosing was highly acceptable.</description><identifier>ISSN: 0010-7824</identifier><identifier>EISSN: 1879-0518</identifier><identifier>DOI: 10.1016/j.contraception.2005.12.011</identifier><identifier>PMID: 16627039</identifier><identifier>CODEN: CCPTAY</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Abortifacient Agents, Nonsteroidal - administration & dosage ; Abortifacient Agents, Steroidal - administration & dosage ; Abortion, Induced - methods ; Administration, Intravaginal ; Administration, Oral ; Adolescent ; Adult ; Biological and medical sciences ; Birth control ; Drug Administration Schedule ; Female ; Genital system. Reproduction ; Gynecology. Andrology. Obstetrics ; Humans ; Induced abortion. Therapeutic abortion ; Medical abortion ; Medical sciences ; Mifepristone ; Mifepristone - administration & dosage ; Misoprostol ; Misoprostol - administration & dosage ; Pharmacology. Drug treatments ; Pilot Projects ; Pregnancy</subject><ispartof>Contraception (Stoneham), 2006-05, Vol.73 (5), p.525-527</ispartof><rights>2006 Elsevier Inc.</rights><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c411t-6e2cba4d3055fd3f37a14e750f8ed9d0aa54343e27f746cfe28a9cf1519c01633</citedby><cites>FETCH-LOGICAL-c411t-6e2cba4d3055fd3f37a14e750f8ed9d0aa54343e27f746cfe28a9cf1519c01633</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17778878$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16627039$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kapp, Nathalie</creatorcontrib><creatorcontrib>Borgatta, Lynn</creatorcontrib><creatorcontrib>Ellis, Sacheen Carr</creatorcontrib><creatorcontrib>Stubblefield, Phillip</creatorcontrib><title>Simultaneous very low dose mifepristone and vaginal misoprostol for medical abortion</title><title>Contraception (Stoneham)</title><addtitle>Contraception</addtitle><description>This pilot study was designed to evaluate the outcome of medical abortion following simultaneous mifepristone (100 mg) and misoprostol (800 μg).
Enrollees had gestational ages up to 56 days and desired a medical abortion. They received 100 mg of mifepristone orally and 800 μg of misoprostol vaginally. Follow-up examination occurred in 2–7 days. A phone call 3 weeks later assessed symptoms and acceptability. A 95% success rate, as seen in higher dose studies, gives a 95% confidence interval of 88–100% for 40 subjects.
Forty women were enrolled; 39 women had follow-up visits. Completed medical abortion was confirmed for 35 (90%) of 39 women. Four women had uterine aspiration. Two patients required repeat misoprostol. Median time from medication to abortion was 7 h. Most women (92%) strongly preferred taking all medications in the clinic.
The simultaneous administration of vaginal misoprostol with 100 mg of oral mifepristone had the outcome of completed abortion within the predicted confidence interval. In addition, simultaneous dosing was highly acceptable.</description><subject>Abortifacient Agents, Nonsteroidal - administration & dosage</subject><subject>Abortifacient Agents, Steroidal - administration & dosage</subject><subject>Abortion, Induced - methods</subject><subject>Administration, Intravaginal</subject><subject>Administration, Oral</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Birth control</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Genital system. Reproduction</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Induced abortion. Therapeutic abortion</subject><subject>Medical abortion</subject><subject>Medical sciences</subject><subject>Mifepristone</subject><subject>Mifepristone - administration & dosage</subject><subject>Misoprostol</subject><subject>Misoprostol - administration & dosage</subject><subject>Pharmacology. Drug treatments</subject><subject>Pilot Projects</subject><subject>Pregnancy</subject><issn>0010-7824</issn><issn>1879-0518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNqNkE1LJDEQhoMoOqv-BWkQvXVblf5IN3taxN0VBA_qOWTSFcnQ0xmTnhH_vTXMgHjzFEg9lbzvI8QlQoGAzc2isGGcorG0mnwYCwlQFygLQDwQM2xVl0ON7aGYASDkqpXVifiV0gIAVFerY3GCTSMVlN1MPD_55XqYzEhhnbINxY9sCO9ZHxJlS-9oFX2awkiZGftsY179aAYepLCKgQdD5kLMltR7y_dmHuI20pk4cmZIdL4_T8XL37vn2__5w-O_-9s_D7mtEKe8IWnnpupLqGvXl65UBitSNbiW-q4HY-qqrEqSyqmqsY5kazrrsMbOsoiyPBXXu3c5zNua0qQ5maVh2NXRjWIZlZQM_t6BllOnSE5zr6WJHxpBb6Xqhf4mVW-lapSapfL2xf6b9Zyrfu3uLTJwtQdMYg8umtH69MUppdpWtczd7ThiKRtPUSfrabSsL5KddB_8jwJ9Aru9nzg</recordid><startdate>20060501</startdate><enddate>20060501</enddate><creator>Kapp, Nathalie</creator><creator>Borgatta, Lynn</creator><creator>Ellis, Sacheen Carr</creator><creator>Stubblefield, Phillip</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20060501</creationdate><title>Simultaneous very low dose mifepristone and vaginal misoprostol for medical abortion</title><author>Kapp, Nathalie ; Borgatta, Lynn ; Ellis, Sacheen Carr ; Stubblefield, Phillip</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c411t-6e2cba4d3055fd3f37a14e750f8ed9d0aa54343e27f746cfe28a9cf1519c01633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Abortifacient Agents, Nonsteroidal - administration & dosage</topic><topic>Abortifacient Agents, Steroidal - administration & dosage</topic><topic>Abortion, Induced - methods</topic><topic>Administration, Intravaginal</topic><topic>Administration, Oral</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Birth control</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Genital system. Reproduction</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Induced abortion. Therapeutic abortion</topic><topic>Medical abortion</topic><topic>Medical sciences</topic><topic>Mifepristone</topic><topic>Mifepristone - administration & dosage</topic><topic>Misoprostol</topic><topic>Misoprostol - administration & dosage</topic><topic>Pharmacology. Drug treatments</topic><topic>Pilot Projects</topic><topic>Pregnancy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kapp, Nathalie</creatorcontrib><creatorcontrib>Borgatta, Lynn</creatorcontrib><creatorcontrib>Ellis, Sacheen Carr</creatorcontrib><creatorcontrib>Stubblefield, Phillip</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Contraception (Stoneham)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kapp, Nathalie</au><au>Borgatta, Lynn</au><au>Ellis, Sacheen Carr</au><au>Stubblefield, Phillip</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Simultaneous very low dose mifepristone and vaginal misoprostol for medical abortion</atitle><jtitle>Contraception (Stoneham)</jtitle><addtitle>Contraception</addtitle><date>2006-05-01</date><risdate>2006</risdate><volume>73</volume><issue>5</issue><spage>525</spage><epage>527</epage><pages>525-527</pages><issn>0010-7824</issn><eissn>1879-0518</eissn><coden>CCPTAY</coden><abstract>This pilot study was designed to evaluate the outcome of medical abortion following simultaneous mifepristone (100 mg) and misoprostol (800 μg).
Enrollees had gestational ages up to 56 days and desired a medical abortion. They received 100 mg of mifepristone orally and 800 μg of misoprostol vaginally. Follow-up examination occurred in 2–7 days. A phone call 3 weeks later assessed symptoms and acceptability. A 95% success rate, as seen in higher dose studies, gives a 95% confidence interval of 88–100% for 40 subjects.
Forty women were enrolled; 39 women had follow-up visits. Completed medical abortion was confirmed for 35 (90%) of 39 women. Four women had uterine aspiration. Two patients required repeat misoprostol. Median time from medication to abortion was 7 h. Most women (92%) strongly preferred taking all medications in the clinic.
The simultaneous administration of vaginal misoprostol with 100 mg of oral mifepristone had the outcome of completed abortion within the predicted confidence interval. In addition, simultaneous dosing was highly acceptable.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>16627039</pmid><doi>10.1016/j.contraception.2005.12.011</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0010-7824 |
| ispartof | Contraception (Stoneham), 2006-05, Vol.73 (5), p.525-527 |
| issn | 0010-7824 1879-0518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67879422 |
| source | Elsevier |
| subjects | Abortifacient Agents, Nonsteroidal - administration & dosage Abortifacient Agents, Steroidal - administration & dosage Abortion, Induced - methods Administration, Intravaginal Administration, Oral Adolescent Adult Biological and medical sciences Birth control Drug Administration Schedule Female Genital system. Reproduction Gynecology. Andrology. Obstetrics Humans Induced abortion. Therapeutic abortion Medical abortion Medical sciences Mifepristone Mifepristone - administration & dosage Misoprostol Misoprostol - administration & dosage Pharmacology. Drug treatments Pilot Projects Pregnancy |
| title | Simultaneous very low dose mifepristone and vaginal misoprostol for medical abortion |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T23%3A18%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Simultaneous%20very%20low%20dose%20mifepristone%20and%20vaginal%20misoprostol%20for%20medical%20abortion&rft.jtitle=Contraception%20(Stoneham)&rft.au=Kapp,%20Nathalie&rft.date=2006-05-01&rft.volume=73&rft.issue=5&rft.spage=525&rft.epage=527&rft.pages=525-527&rft.issn=0010-7824&rft.eissn=1879-0518&rft.coden=CCPTAY&rft_id=info:doi/10.1016/j.contraception.2005.12.011&rft_dat=%3Cproquest_cross%3E67879422%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c411t-6e2cba4d3055fd3f37a14e750f8ed9d0aa54343e27f746cfe28a9cf1519c01633%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=67879422&rft_id=info:pmid/16627039&rfr_iscdi=true |